-
Product Insights
NewLikelihood of Approval Analysis for Lyssavirus infections
Overview How likely is it that the drugs in Lyssavirus infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lyssavirus infections Overview The infections caused by a group of lyssaviruses are...
-
Product Insights
NewLikelihood of Approval Analysis for Paramyxoviridae Infections
Overview How likely is it that the drugs in Paramyxoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paramyxoviridae Infections Overview The Paramyxoviridae family belongs to the order Mononegavirales, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OTO-413 in Hearing Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OTO-413 in Hearing Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OTO-413 in Hearing Disorders Drug Details: OTO-413 is under development for the...
-
Product Insights
Net Present Value Model: OTO-413
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model OTO-413 Drug Details OTO-413 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OTO-413
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OTO-413 Drug Details OTO-413 is under development for the repair of cochlear synaptopathy and...
-
Product Insights
Alzheimer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020
Alzheimer Diagnostic Tests are test that detects the disease before it causes the symptoms. It measures key proteins or protein patterns in blood or spinal fluid (biomarkers). GlobalData's Medical Devices sector report, “Alzheimer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Alzheimer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Alzheimer Diagnostic Tests Pipeline Assessment report provides key information...
-
Sector Analysis
PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by impaired memory and thinking (known as dementia), and functional decline. With a rapidly accelerating worldwide prevalence, there is a growing societal pressure for curative treatment for AD patients. The burden of AD encompasses clinical burden to patients as well as economic burden to payers and patients and caregiver burden, adding to the urgent need for improved AD therapy. Significant efforts are being made to develop a new treatment...
-
Sector Analysis
OpportunityAnalyzer: Fragile X Syndrome – Opportunity Analysis and Forecasts to 2026
In this report, GlobalData analyzes the nuances of the Fragile X Syndrome (FXS) treatment landscape and provides detailed insights into the market dynamics of this highly competitive space. The analysis also includes the evaluation of the commercial and clinical profiles of pipeline drugs, and their sales forecasts for the Fragile X Syndrome indication over the 2016–2026 period. Although a relatively rare disease, Fragile X Syndrome has a distinct underlying genetic cause. Early intervention is key to the prognosis of the...
-
Sector Analysis
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...